{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:09:07Z","timestamp":1761743347146},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T00:00:00Z","timestamp":1271808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s10555-010-9218-3","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T01:36:47Z","timestamp":1271727407000},"page":"339-350","source":"Crossref","is-referenced-by-count":13,"title":["Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal"],"prefix":"10.1007","volume":"29","author":[{"given":"Andrea","family":"Tinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Malvasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pisan\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"issue":"10","key":"9218_CR1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/138920209788488553","volume":"4","author":"A Tinelli","year":"2009","unstructured":"Tinelli, A., Vergara, D., Martignago, R., Leo, G., Pisan\u00f2, M., & Malvasi, A. (2009). An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Current Genomics, 4(10), 240\u2013249.","journal-title":"Current Genomics"},{"key":"9218_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","volume":"20","author":"R Sankaranarayanan","year":"2006","unstructured":"Sankaranarayanan, R., & Ferlay, J. (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Practice & Research Clinical Obstetrics Gynaecology, 20, 207\u2013225.","journal-title":"Best Practice & Research Clinical Obstetrics Gynaecology"},{"key":"9218_CR3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2003.05.096","volume":"21","author":"HT Lynch","year":"2003","unstructured":"Lynch, H. T., Snyder, C. L., Lynch, J. F., Riley, B. D., & Rubinstein, W. S. (2003). Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. Journal of Clinical Oncology, 21, 740\u2013753.","journal-title":"Journal of Clinical Oncology"},{"key":"9218_CR4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.1972.03210130023005","volume":"222","author":"HT Lynch","year":"1972","unstructured":"Lynch, H. T., Krush, A. J., Lemon, H. M., et al. (1972). Tumor variation in families with breast cancer. Jama, 222, 1631\u20131635.","journal-title":"Jama"},{"issue":"4","key":"9218_CR5","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/02841860802004974","volume":"47","author":"FC Nielsen","year":"2008","unstructured":"Nielsen, F. C., Kruse, T. A., & Gerdes, A. M. (2008). BRCA1 and BRCA2 mutations in Danish families with hereditary breast and\/or ovarian cancer. Acta Oncologica, 47(4), 772\u2013777.","journal-title":"Acta Oncologica"},{"key":"9218_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10689-005-2571-7","volume":"5","author":"OM Sinilnikova","year":"2006","unstructured":"Sinilnikova, O. M., Mazoyer, S., Bonnardel, C., Lynch, H. T., Narod, S. A., & Lenoir, G. M. (2006). BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high-risk families. Familial Cancer, 5, 15\u201320.","journal-title":"Familial Cancer"},{"issue":"3","key":"9218_CR7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02710121","volume":"6","author":"J Brunet","year":"2004","unstructured":"Brunet, J., & P\u00e8rez-Segura, P. (2004). Cancer screening and genetic counselling. Reviews in oncology, 6(3), 176\u2013183.","journal-title":"Reviews in oncology"},{"key":"9218_CR8","unstructured":"Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer ES, et al. (eds). SEER Cancer Statistics Review, 1975 \u2013 2004, National Cancer Institute, Bethesda, http:\/\/seer.cancer.gov\/csr\/1975_2004\/ , based on November 2006 SEER data submission, posted to the SEER website 2007"},{"key":"9218_CR9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2004.10.037","volume":"96","author":"AW Kurian","year":"2005","unstructured":"Kurian, A. W., Balise, R. R., McGuire, V., & Whittemore, A. S. (2005). Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecologic Oncology, 96, 520\u2013530.","journal-title":"Gynecologic Oncology"},{"key":"9218_CR10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.ejca.2007.01.035","volume":"43","author":"F Chiaffarino","year":"2007","unstructured":"Chiaffarino, F., Parazzini, F., Bosetti, C., Franceschi, S., Talamini, R., Canzonieri, V., et al. (2007). Risk factors for ovarian cancer histotypes. European Journal of Cancer, 43, 1208\u20131213.","journal-title":"European Journal of Cancer"},{"key":"9218_CR11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ijc.20649","volume":"113","author":"F Bray","year":"2005","unstructured":"Bray, F., Loos, A. H., Tognazzo, S., & La Vecchia, C. (2005). Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953\u20132000. International Journal of Cancer, 113, 977\u2013990.","journal-title":"International Journal of Cancer"},{"key":"9218_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0959-8049(02)00743-8","volume":"39","author":"E Negri","year":"2003","unstructured":"Negri, E., Pelucchi, C., Franceschi, S., Montella, M., Conti, E., Dal Maso, L., et al. (2003). Family history of cancer and risk of ovarian cancer. European Journal of Cancer, 39, 505\u2013510.","journal-title":"European Journal of Cancer"},{"key":"9218_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00008469-200104000-00002","volume":"10","author":"C Vecchia La","year":"2001","unstructured":"La Vecchia, C. (2001). Epidemiology of ovarian cancer: a summary review. European Journal of Cancer Prevention, 10, 125\u2013129.","journal-title":"European Journal of Cancer Prevention"},{"key":"9218_CR14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/978-1-59745-416-2_25","volume":"471","author":"MS Simon","year":"2009","unstructured":"Simon, M. S., & Petrucelli, N. (2009). Hereditary breast and ovarian cancer syndrome: the impact of race on uptake of genetic counseling and testing. Methods in Molecular Biology, 471, 487\u2013500.","journal-title":"Methods in Molecular Biology"},{"key":"9218_CR15","first-page":"3168","volume":"56","author":"Y Chen","year":"1996","unstructured":"Chen, Y., Farmer, A. A., Chen, C. F., Jones, D. C., Chen, P. L., & Lee, W. H. (1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Research, 56, 3168\u20133172.","journal-title":"Cancer Research"},{"key":"9218_CR16","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1073\/pnas.94.14.7138","volume":"94","author":"H Ruffner","year":"1997","unstructured":"Ruffner, H., & Verma, I. M. (1997). BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proceedings of the National Academy of Sciences of the United States of America, 94, 7138\u20137143.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"9218_CR17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/nar\/gkl010","volume":"34","author":"CX Deng","year":"2006","unstructured":"Deng, C. X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Research, 34(5), 1416\u20131426.","journal-title":"Nucleic Acids Research"},{"key":"9218_CR18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.1088753","volume":"302","author":"XC Yu","year":"2003","unstructured":"Yu, X. C., CC, He M., Mer, G., & Chen, J. (2003). The BRCT domain is a phospho-protein binding domain. Science, 302, 639\u2013642.","journal-title":"Science"},{"key":"9218_CR19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1088877","volume":"302","author":"IA Manke","year":"2003","unstructured":"Manke, I. A., Lowery, D. M., Nguyen, A., & Yaffe, M. B. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science, 302, 636\u2013639.","journal-title":"Science"},{"key":"9218_CR20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10147-004-0423-3","volume":"9","author":"M Arai","year":"2004","unstructured":"Arai, M., Utsunomiya, J., & Miki, Y. (2004). Familial breast and ovarian cancers. International Journal of Clinical Oncology, 9, 270\u2013282.","journal-title":"International Journal of Clinical Oncology"},{"issue":"5","key":"9218_CR21","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1073\/pnas.95.5.2302","volume":"95","author":"T Ouchi","year":"1998","unstructured":"Ouchi, T., Monteiro, A. N., August, A., Aaronson, S. A., & Hanafusa, H. (1998). BRCA1 regulates p53-dependent gene expression. Proceedings of the National Academy of Sciences of the United States of America, 95(5), 2302\u20132306.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"9218_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.onc.1204073","volume":"20","author":"S Fan","year":"2001","unstructured":"Fan, S., Yong, X., Wang, C., Yuan, R. Q., Meng, Q., Wang, J. A., et al. (2001). Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene, 20(1), 77\u201387.","journal-title":"Oncogene"},{"issue":"17","key":"9218_CR23","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.171174298","volume":"98","author":"L Zheng","year":"2001","unstructured":"Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., & Boyer, T. G. (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9587\u20139592.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9218_CR24","doi-asserted-by":"crossref","first-page":"13078","DOI":"10.1073\/pnas.93.23.13078","volume":"93","author":"JV Rajan","year":"1996","unstructured":"Rajan, J. V., Wang, M., Marquis, S. T., & Chodosh, L. A. (1996). Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proceedings of the National Academy of Sciences, 93, 13078\u201313083.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9218_CR25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/386804a0","volume":"386","author":"SK Sharan","year":"1997","unstructured":"Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., et al. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature, 386, 804\u2013810.","journal-title":"Nature"},{"issue":"23","key":"9218_CR26","doi-asserted-by":"crossref","first-page":"13869","DOI":"10.1073\/pnas.95.23.13869","volume":"95","author":"LY Marmorstein","year":"1998","unstructured":"Marmorstein, L. Y., Ouchi, T., & Stuart, A. A. (1998). The BRCA2 gene product functionally interacts with p53 and RAD51. Proceedings of the National Academy of Sciences of the United States of America, 95(23), 13869\u201313874.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"9218_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11764-008-0077-7","volume":"3","author":"CB Crotser","year":"2009","unstructured":"Crotser, C. B., & Boehmke, M. (2009). Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science. Journal of Cancer Survival, 3(1), 21\u201342.","journal-title":"Journal of Cancer Survival"},{"issue":"1","key":"9218_CR28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2008.06.003","volume":"69","author":"A Russo","year":"2009","unstructured":"Russo, A., Cal\u00f2, V., Bruno, L., Rizzo, S., Bazan, V., & Di Fede, G. (2009). Hereditary ovarian cancer. Critical Reviews in Oncology\/Hematology, 69(1), 28\u201344.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"4","key":"9218_CR29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","volume":"124","author":"NM Velde van der","year":"2009","unstructured":"van der Velde, N. M., Mourits, M. J., Arts, H. J., de Vries, J., Leegte, B. K., Dijkhuis, G., et al. (2009). Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers? International Journal of Cancer, 124(4), 919\u2013923.","journal-title":"International Journal of Cancer"},{"key":"9218_CR30","doi-asserted-by":"crossref","unstructured":"Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005). U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 143(5), 362\u2013379.","DOI":"10.7326\/0003-4819-143-5-200509060-00012"},{"issue":"4","key":"9218_CR31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ogc.2007.09.005","volume":"34","author":"M Thomassen","year":"2007","unstructured":"Thomassen, M., Hansen, T. V., Borg, A., Lianee, H. T., Wikman, F., Pedersen, I. S., et al. (2007). Hereditary ovarian cancer\u2014assessing risk and prevention strategies. Obstetrics and Gynecology Clinics of North America, 34(4), 651\u2013665.","journal-title":"Obstetrics and Gynecology Clinics of North America"},{"issue":"2","key":"9218_CR32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/10906570260199348","volume":"6","author":"CS Skinner","year":"2002","unstructured":"Skinner, C. S., Schildkraut, J. M., Berry, D., Calingaert, B., Marcom, P. K., Sugarman, J., et al. (2002). Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genetis Testing, 6(2), 93\u2013105.","journal-title":"Genetis Testing"},{"issue":"1","key":"9218_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/gte.2005.9.48","volume":"9","author":"N Peters","year":"2005","unstructured":"Peters, N., Domchek, S. M., Rose, A., Polis, R., Stopfer, J., & Armstrong, K. (2005). Knowledge, attitudes, and utilization of BRCA1\/2 testing among women with early onset breast cancer. Genet Test, 9(1), 48\u201353.","journal-title":"Genet Test"},{"issue":"3","key":"9218_CR34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.soncn.2004.04.005","volume":"20","author":"ST Vadaparampil","year":"2004","unstructured":"Vadaparampil, S. T., Wey, J. P., & Kinney, A. Y. (2004). Psychosocial aspects of genetic counseling and testing. Seminars in Oncology Nursing, 20(3), 186\u2013195.","journal-title":"Seminars in Oncology Nursing"},{"issue":"5","key":"9218_CR35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/j.seminoncol.2007.07.004","volume":"34","author":"SM Kehoe","year":"2007","unstructured":"Kehoe, S. M., & Kauff, N. D. (2007). Screening and prevention of hereditary gynecologic cancers. Seminars in Oncology, 34(5), 406\u2013410.","journal-title":"Seminars in Oncology"},{"key":"9218_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00109-005-0696-7","volume":"84","author":"MP Lux","year":"2006","unstructured":"Lux, M. P., Fasching, P. A., & Beckmann, M. W. (2006). Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine, 84, 16\u201328.","journal-title":"Journal of Molecular Medicine"},{"key":"9218_CR37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/jmg.40.7.503","volume":"40","author":"M Hoya De la","year":"2003","unstructured":"De la Hoya, M., Diez, O., P\u00e9rez-Segura, P., et al. (2003). Pre-test prediction models of BRCA1 or BRCA2 mutation in breast\/ovarian families attending familial cancer clinics. Journal of Medical Genetics, 40, 503\u2013510.","journal-title":"Journal of Medical Genetics"},{"key":"9218_CR38","first-page":"1","volume":"145","author":"ER Myers","year":"2006","unstructured":"Myers, E. R., Havrilesky, L. J., Kulasingam, S. L., Sanders, G. D., Cline, K. E., Gray, R. N., et al. (2006). Genomic tests for ovarian cancer detection and management. Evidence Report\/Technology Assessment (full report), 145, 1\u2013100.","journal-title":"Evidence Report\/Technology Assessment (full report)"},{"issue":"1","key":"9218_CR39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12160-007-9004-9","volume":"35","author":"CA Low","year":"2008","unstructured":"Low, C. A., Bower, J. E., Kwan, L., & Seldon, J. (2008). Benefit finding in response to BRCA1\/2 testing. Annals of Behavioral Medicine, 35(1), 61\u201369.","journal-title":"Annals of Behavioral Medicine"},{"issue":"1","key":"9218_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/gte.2006.9999","volume":"11","author":"S Kieran","year":"2007","unstructured":"Kieran, S., Loescher, L. J., & Lim, K. H. (2007). The role of financial factors in acceptance of clinical BRCA genetic testing. Genetic Testing, 11(1), 101\u2013110.","journal-title":"Genetic Testing"},{"issue":"5","key":"9218_CR41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01720610-200805000-00008","volume":"21","author":"LM Herman","year":"2008","unstructured":"Herman, L. M. (2008). Clinical and Scientific Affairs Council of the AAPA. Hereditary breast and ovarian cancers. JAAPA, 21(5), 18\u201321.","journal-title":"JAAPA"},{"issue":"1","key":"9218_CR42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2008.06.016","volume":"111","author":"RA Lacour","year":"2008","unstructured":"Lacour, R. A., Daniels, M. S., Westin, S. N., Meyer, L. A., Burke, C. C., Burns, K. A., et al. (2008). What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology, 111(1), 132\u2013136.","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"9218_CR43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1369-7625.2008.00494.x","volume":"11","author":"AD Bakos","year":"2008","unstructured":"Bakos, A. D., Hutson, S. P., Loud, J. T., Peters, J. A., Giusti, R. M., & Greene, M. H. (2008). BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expectations, 11(3), 220\u2013231.","journal-title":"Health Expectations"},{"issue":"1","key":"9218_CR44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1188\/06.CJON.77-81","volume":"10","author":"MM Fields","year":"2006","unstructured":"Fields, M. M., & Chevlen, E. (2006). Ovarian cancer screening: a look at the evidence. Clinical Journal of Oncology Nursing, 10(1), 77\u201381.","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"9218_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000052963","volume":"52","author":"F Wakahara","year":"2001","unstructured":"Wakahara, F., Kikkawa, F., Nawa, A., et al. (2001). Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecologic and Obstetric Investigation, 52, 147\u2013152.","journal-title":"Gynecologic and Obstetric Investigation"},{"issue":"12","key":"9218_CR46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","volume":"114","author":"ER Woodward","year":"2007","unstructured":"Woodward, E. R., Sleightholme, H. V., Considine, A. M., Williamson, S., McHugo, J. M., & Cruger, D. G. (2007). Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG, 114(12), 1500\u20131509.","journal-title":"BJOG"},{"issue":"963","key":"9218_CR47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1259\/bjr\/21074350","volume":"81","author":"MJ Bermejo-P\u00e9rez","year":"2008","unstructured":"Bermejo-P\u00e9rez, M. J., M\u00e1rquez-Calder\u00f3n, S., & Llanos-M\u00e9ndez, A. (2008). Cancer surveillance based on imaging techniques in carriers of BRCA1\/2 gene mutations: a systematic review. British Journal of Radiology, 81(963), 172\u2013179.","journal-title":"British Journal of Radiology"},{"issue":"2","key":"9218_CR48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ajmg.a.30566","volume":"133A","author":"A McInerney-Leo","year":"2005","unstructured":"McInerney-Leo, A., Biesecker, B. B., Hadley, D. W., Kase, R. G., Giambarresi, T. R., Johnson, E., et al. (2005). BRCA1\/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. American Journal of Medical Genetics, 133A(2), 165\u2013169.","journal-title":"American Journal of Medical Genetics"},{"issue":"5","key":"9218_CR49","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/01.AOG.0000239105.39149.d8","volume":"108","author":"JV Lacey Jr","year":"2006","unstructured":"Lacey, J. V., Jr., Greene, M. H., Buys, S. S., Reding, D., Riley, T. L., Berg, C. D., et al. (2006). Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstetrics and Gynecology, 108(5), 1176\u20131184.","journal-title":"Obstetrics and Gynecology"},{"key":"9218_CR50","first-page":"1","volume":"130","author":"ER Myers","year":"2006","unstructured":"Myers, E. R., Bastian, L. A., Havrilesky, L. J., Kulasingam, S. L., Terplan, M. S., Cline, K. E., et al. (2006). Management of adnexal mass. Evidence Report\/Technology Assessment, 130, 1\u2013145.","journal-title":"Evidence Report\/Technology Assessment"},{"key":"9218_CR51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","volume":"174","author":"RC Bast Jr","year":"2007","unstructured":"Bast, R. C., Jr., Brewer, M., Zou, C., Hernandez, M. A., Daley, M., Ozols, R., et al. (2007). Prevention and early detection of ovarian cancer: mission impossible? Recent Results in Cancer Research, 174, 91\u2013100.","journal-title":"Recent Results in Cancer Research"},{"key":"9218_CR52","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJM200112063452312","volume":"345","author":"SA Narod","year":"2001","unstructured":"Narod, S. A., Sun, P., & Risch, H. A. (2001). Ovarian cancer, oral contraceptives, and BRCA mutations. New England Journal of Medicine, 345, 1706\u20131707.","journal-title":"New England Journal of Medicine"},{"key":"9218_CR53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","volume":"345","author":"B Modan","year":"2001","unstructured":"Modan, B., Hartge, P., Hirsh-Yechezkel, G., et al. (2001). Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 345, 235\u2013240.","journal-title":"New England Journal of Medicine"},{"key":"9218_CR54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/90.8.597","volume":"90","author":"AL Sabichi","year":"1998","unstructured":"Sabichi, A. L., Hendricks, D. T., Bober, M. A., & Birrer, M. J. (1998). Retinoic acid receptor beta expression and growth inhibition of gynaecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Journal of the National Cancer Institute, 90, 597\u2013605.","journal-title":"Journal of the National Cancer Institute"},{"key":"9218_CR55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D","volume":"65","author":"R Supino","year":"1996","unstructured":"Supino, R., Crosti, M., Clerici, M., et al. (1996). Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. International Journal of Cancer, 65, 491\u2013497.","journal-title":"International Journal of Cancer"},{"issue":"22","key":"9218_CR56","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1021\/jm970196m","volume":"40","author":"DM Benbrook","year":"1997","unstructured":"Benbrook, D. M., Madler, M. M., Spruce, L. W., Birckbichler, P. J., Nelson, E. C., Subramanian, S., et al. (1997). Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. Journal of Medicinal Chemistry, 40(22), 3567\u20133583.","journal-title":"Journal of Medicinal Chemistry"},{"key":"9218_CR57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/93.7.516","volume":"93","author":"S Guruswamy","year":"2001","unstructured":"Guruswamy, S., Lightfoot, S., Gold, M. A., Hassan, R., Berlin, K. D., Ivey, R. T., et al. (2001). Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. Journal of the National Cancer Institute, 93, 516\u2013525.","journal-title":"Journal of the National Cancer Institute"},{"key":"9218_CR58","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/ije\/23.6.1133","volume":"23","author":"ES Lefkowitz","year":"1994","unstructured":"Lefkowitz, E. S., & Garland, C. F. (1994). Sunlight, vitamin D, and ovarian cancer mortality rates in US women. International Journal of Epidemiology, 23, 1133\u20131136.","journal-title":"International Journal of Epidemiology"},{"key":"9218_CR59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO;2-E","volume":"86","author":"MH Ahonen","year":"2000","unstructured":"Ahonen, M. H., Zhuang, Y. H., Aine, R., Ylikomi, T., & Tuohimaa, P. (2000). Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. International Journal of Cancer, 86, 40\u201346.","journal-title":"International Journal of Cancer"},{"key":"9218_CR60","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/jnci\/91.17.1459","volume":"91","author":"RB Ness","year":"1999","unstructured":"Ness, R. B., & Cottreau, C. (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute, 91, 1459\u20131467.","journal-title":"Journal of the National Cancer Institute"},{"key":"9218_CR61","first-page":"903","volume":"10","author":"KB Moysich","year":"2001","unstructured":"Moysich, K. B., Mettlin, C., Piver, M. S., Natarajan, N., Menezes, R. J., & Swede, H. (2001). Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 10, 903\u2013906.","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"9218_CR62","first-page":"933","volume":"9","author":"L Rosenberg","year":"2000","unstructured":"Rosenberg, L., Palmer, J. R., Rao, R. S., Coogan, P. F., Strom, B. L., Zauber, A. G., et al. (2000). A case-control study of analgesic use and ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention, 9, 933\u2013937.","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"9218_CR63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(97)08064-1","volume":"351","author":"DW Cramer","year":"1998","unstructured":"Cramer, D. W., Harlow, B. L., Titus-Ernstoff, L., Bohlke, K., Welch, W. R., & Greenberg, E. R. (1998). Over-the-counter analgesics and risk of ovarian cancer. Lancet, 351, 104\u2013107.","journal-title":"Lancet"},{"key":"9218_CR64","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/90.20.1529","volume":"90","author":"MM Taketo","year":"1998","unstructured":"Taketo, M. M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Journal of the National Cancer Institute, 90, 1529\u20131536.","journal-title":"Journal of the National Cancer Institute"},{"key":"9218_CR65","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/jnci\/90.21.1609","volume":"90","author":"MM Taketo","year":"1998","unstructured":"Taketo, M. M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). Journal of the National Cancer Institute, 90, 1609\u20131620.","journal-title":"Journal of the National Cancer Institute"},{"key":"9218_CR66","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","volume":"18","author":"CS Williams","year":"1999","unstructured":"Williams, C. S., Mann, M., & DuBois, R. N. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18, 7908\u20137916.","journal-title":"Oncogene"},{"key":"9218_CR67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0165-6147(00)01559-5","volume":"21","author":"GJ Murphy","year":"2000","unstructured":"Murphy, G. J., & Holder, J. C. (2000). PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends in Pharmacological Sciences, 21, 469\u2013474.","journal-title":"Trends in Pharmacological Sciences"},{"key":"9218_CR68","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1172\/JCI119870","volume":"100","author":"M Adams","year":"1997","unstructured":"Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., et al. (1997). Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation, 100, 3149\u20133153.","journal-title":"Journal of Clinical Investigation"},{"key":"9218_CR69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"E Mueller","year":"1998","unstructured":"Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., et al. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell, 1, 465\u2013470.","journal-title":"Molecular Cell"},{"issue":"3","key":"9218_CR70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00268-006-0616-1","volume":"31","author":"YN You","year":"2007","unstructured":"You, Y. N., Lakhani, V. T., & Wells, S. A., Jr. (2007). The role of prophylactic surgery in cancer prevention. World Journal of Surgery, 31(3), 450\u2013464.","journal-title":"World Journal of Surgery"},{"issue":"1","key":"9218_CR71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/GCO.0b013e32801195da","volume":"19","author":"SM Domchek","year":"2007","unstructured":"Domchek, S. M., & Rebbeck, T. R. (2007). Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology, 19(1), 27\u201330.","journal-title":"Current Opinion in Obstetrics and Gynecology"},{"issue":"1","key":"9218_CR72","first-page":"231","volume":"111","author":"ACOG Practice Bulletin No. 89","year":"2008","unstructured":"ACOG Practice Bulletin No. 89. (2008). Elective and risk-reducing salpingo-oophorectomy. Obstetrici\u00c2a ginecologi\u00c2a, 111(1), 231\u2013241.","journal-title":"Obstetrici\u00c2a ginecologi\u00c2a"},{"issue":"28","key":"9218_CR73","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2005.04.5260","volume":"24","author":"JG Guillem","year":"2006","unstructured":"Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., et al. (2006). Offit K; ASCO; SSO. ASCO\/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology, 24(28), 4642\u20134660.","journal-title":"Journal of Clinical Oncology"},{"key":"9218_CR74","first-page":"43","volume-title":"New technology frontiers in minimally invasive therapies","author":"A Tinelli","year":"2007","unstructured":"Tinelli, A., Malvasi, A., Casciaro, S., Leo, G., Vergara, D., Pisan\u00f2, M., et al. (2007). Tailoring minimally invasive gynaecological surgery based on biogenomic findings. In S. Casciaro & B. Gersak (Eds.), New technology frontiers in minimally invasive therapies (pp. 43\u201362). Italy: Lupiensis Biomedical Publications. 6."},{"issue":"2","key":"9218_CR75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","volume":"107","author":"JM Lancaster","year":"2007","unstructured":"Lancaster, J. M., Powell, C. B., Kauff, N. D., Cass, I., Chen, L. M., Lu, K. H., et al. (2007). Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 107(2), 159\u2013162.","journal-title":"Gynecologic Oncology"},{"key":"9218_CR76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-8-101","volume":"8","author":"LI Batista","year":"2008","unstructured":"Batista, L. I., Lu, K. H., Beahm, E. K., Arun, B. K., Bodurka, D. C., & Meric-Bernstam, F. (2008). Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer, 8, 101.","journal-title":"BMC Cancer"},{"key":"9218_CR77","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Garc\u00eda EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FBL, Hoogerbrugge N, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Research. 2009;11(1): R8.","DOI":"10.1186\/bcr2223"},{"issue":"2","key":"9218_CR78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80\u201387.","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"9218_CR79","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","volume":"17","author":"MH Greene","year":"2008","unstructured":"Greene, M. H., Piedmonte, M., Alberts, D., Gail, M., Hensley, M., Miner, Z., et al. (2008). A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiology, Biomarkers and Prevention, 17(3), 594\u2013604.","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"issue":"4","key":"9218_CR80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","volume":"10","author":"U Menon","year":"2009","unstructured":"Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, 10(4), 327\u2013340.","journal-title":"Lancet Oncology"},{"issue":"4","key":"9218_CR81","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","volume":"113","author":"E Partridge","year":"2009","unstructured":"Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J. L., Church, T. R., et al. (2009). Results from four rounds of ovarian cancer screening in a randomized trial. Obstetrics and Gynecology, 113(4), 775\u2013782.","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"9218_CR82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222\u2013231.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-010-9218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-010-9218-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-010-9218-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:20:02Z","timestamp":1559236802000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-010-9218-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["9218"],"URL":"https:\/\/doi.org\/10.1007\/s10555-010-9218-3","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,21]]}}}